Deutsche Biotech Innovativ AG Categories
Germany Healthcare BiotechnologyGermany Healthcare Germany Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Deutsche Biotech Innovativ AG operates as a biotechnology company in Germany. The company develops Adrecizumab, an antibody-based therapy which is in Phase II clinical trial for the treatment of septic shock. It also focuses on the development of various drugs for the treatment of solid tumor, organ failure, rosacea, eczema, throat inflammation, and Alzheimer's diseases. The company was formerly known as Venetus Beteiligungen AG and changed its name to Deutsche Biotech Innovativ AG in August 2014. Deutsche Biotech Innovativ AG is based in Hennigsdorf, Germany.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Deutsche Biotech Innovativ AG has the following listings and related stock indices.
Stock: FSX: DBI wb_incandescent
Stock: XDUS: DBI wb_incandescent
Stock: XETR: DBI wb_incandescent